Humana (NYSE:HUM) Price Target Raised to $602.00

Humana (NYSE:HUM) had its price objective boosted by Wells Fargo & Company from $502.00 to $602.00 in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the insurance provider’s stock.

Several other research firms have also weighed in on HUM. Raymond James Financial reissued an “outperform” rating on shares of Humana in a research report on Friday, November 6th. Lake Street Capital began coverage on Humana in a research note on Thursday, July 30th. They issued a “buy” rating on the stock. HSBC lowered Humana to a “hold” rating in a research report on Thursday, July 30th. UBS Group raised their target price on Humana from $405.00 to $495.00 and gave the stock a “neutral” rating in a research note on Monday, October 12th. Finally, Mizuho lifted their target price on Humana from $468.00 to $495.00 and gave the stock an “outperform” rating in a report on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $476.52.

Humana Trading Up 1.5%

Shares of NYSE HUM traded up $6.70 during midday trading on Thursday, reaching $450.38. The stock had a trading volume of 1,499,042 shares, compared to its average volume of 1,566,553. The firm has a market cap of $54.09 billion, a price-to-earnings ratio of 43.81, a price-to-earnings-growth ratio of 2.11 and a beta of 0.65. Humana has a twelve month low of $163.11 and a twelve month high of $456.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.74 and a current ratio of 1.65. The company’s 50 day moving average price is $408.53 and its 200 day moving average price is $316.91.

Humana (NYSE:HUM) last posted its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.30. Humana had a net margin of 0.81% and a return on equity of 8.50%. The company had revenue of $41.16 billion during the quarter, compared to analysts’ expectations of $40.87 billion. During the same period in the prior year, the company posted $3.24 earnings per share. Humana’s revenue for the quarter was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, sell-side analysts expect that Humana will post 9.66 EPS for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 24th will be paid a $0.8850 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s dividend payout ratio (DPR) is 34.44%.

Insider Activity at Humana

In other news, insider Joseph Ventura sold 5,495 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the completion of the sale, the insider owned 21,910 shares in the company, valued at $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Humana

Several hedge funds have recently bought and sold shares of HUM. BlackRock Inc. bought a new position in shares of Humana in the second quarter valued at $4,138,160,000. Pzena Investment Management LLC bought a new stake in shares of Humana during the second quarter worth about $1,749,014,000. Assenagon Asset Management S.A. increased its position in shares of Humana by 20,126.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock worth $479,053,000 after acquiring an additional 1,249,272 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Humana in the 2nd quarter worth about $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in shares of Humana in the 2nd quarter worth about $314,922,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.